单药与多药血管扩张剂治疗脑血管痉挛:多药是否更优?
该回顾性研究比较动脉内单药(尼卡地平或维拉帕米)与多药(硝酸甘油、维拉帕米、尼卡地平)治疗动脉瘤性蛛网膜下腔出血后脑血管痉挛的疗效。116例患者中,多药组血管直径改善率更高(中位PIIR 34.9% vs 10.5%,p<0.0001),且出院时和90天随访功能预后更优。
要点
- 多药动脉内血管扩张剂较单药显著提高血管直径改善率。
- 多药治疗与出院时及90天功能预后更优独立相关。
- 需前瞻性研究验证最佳血管扩张剂组合方案。
核心结论
- 动脉内多药血管扩张剂治疗脑血管痉挛较单药增加血管反应并改善功能预后。
研究设计与样本
- 回顾性研究,纳入116例aSAH合并脑血管痉挛并接受动脉内血管扩张剂治疗的患者。
- 组1(2008-2011年,N=47)接受单药尼卡地平或维拉帕米,组2(2010-2016年,N=69)接受硝酸甘油、维拉帕米和尼卡地平多药方案。
- 比较两组输注后改善率(PIIR),并用多因素logistic回归分析功能预后(改良Rankin量表)。
主要发现
- 多药治疗较单药使血管直径改善率提高24.36%(中位PIIR:组1 10.5% [IQR 5.3-21.1%] vs 组2 34.9% [IQR 21.4-66.0%],p<0.0001)。
- 调整后多因素回归显示,多药治疗与出院时功能预后更优相关(OR 0.15,95%CI 0.04-0.55;p<0.01)。
- 多药治疗与90天随访功能预后更优相关(OR 0.20,95%CI 0.05-0.77;p<0.05)。
临床怎么用
- 对于aSAH后脑血管痉挛,可考虑动脉内多药血管扩张剂联合方案以增强血管反应。
- 多药方案可能与更好的出院及90天功能预后相关,但需个体化评估。
局限性
- 回顾性研究设计,存在选择偏倚和信息偏倚可能。
- 两组时间跨度不同,治疗策略可能随时间变化。
- 样本量有限,未报告多药方案的安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with cerebral vasospasm caused by aneurysmal subarachnoid hemorrhage (aSAH) are often treated with intra-arterial (IA) vasodilator infusion. However, the optimal drug regimen is yet to be elucidated. METHODS: A retrospective review of patients with aSAH and cerebral vasospasm treated with IA vasodilator infusion was performed. Patients in group 1 (2008-2011) were treated with a single agent, either nicardipine or verapamil, and patients in group 2 (2010-2016) were treated with a regimen of nitroglycerin, verapamil, and nicardipine. The post-infusion improvement ratio (PIIR) was compared between groups. Adjusted multivariate logistic regression models were utilized to determine whether patients treated with multiple vasodilators had an improved functional outcome, defined by the modified Rankin Scale, at discharge and 90-day follow-up. RESULTS: Among 116 patients from group 1 (N = 47) and group 2 (N = 69), the median age was 54.5 years [IQR, 46-53 years] and 78% were female. Use of multiple-agent therapy resulted in a 24.36% improvement in vessel diameter over single-agent therapy (median PIIR: group 1, 10.5% [IQR, 5.3-21.1%] vs group 2, 34.9% [IQR, 21.4-66.0%]; p < 0.0001). In the adjusted multivariate logistic regression, the use of multiple-agent therapy was associated with a better functional outcome at discharge (OR 0.15, 95% CI [0.04-0.55]; p < 0.01) and at 90-day follow-up (OR 0.20, 95% CI [0.05-0.77]; p < 0.05) when compared to single-agent therapy. CONCLUSION: In this study, we found that patients treated for cerebral vasospasm with IA infusion of multiple vasodilators had an increased vessel response and better functional outcomes compared to those treated with a single agent.
引用
- Chen PR, Bulsara K, Lopez-Rivera V, et al. Use of single versus multiple vasodilator agents in the treatment of cerebral vasospasm: is more better than less? Acta Neurochir (Wien). 2020. PMID: 32533411. doi:10.1007/s00701-020-04415-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。